TLSA (Tiziana Life Sciences) ROCE %: -389.08% (As of Dec. 2025)


TLSA Tiziana Life Sciences Ltd TLSA
30 GF Score
Price $1.15
! 2 Warning Signs
View Full Analysis

What is Tiziana Life Sciences ROCE %?

Tiziana Life Sciences TLSA +2.23% 30 ROCE % is -389.08% as of Dec. 2025. GuruFocus rates TLSA with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tiziana Life Sciences's annualized ROCE % for the quarter that ended in Dec. 2025 was -389.08%.

Tiziana Life Sciences  (NAS:TLSA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tiziana Life Sciences ROCE % Related Terms

Tiziana Life Sciences ROCE % Historical Data

* Premium members only.

The historical data trend for Tiziana Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tiziana Life Sciences ROCE % Chart

Tiziana Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -50.95 -50.28 -135.37 -349.44 -872.24

Tiziana Life Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -180.31 -345.34 -702.33 -279.72 -389.08
TLSA
30GF Score
Tiziana Life Sciences Ltd TLSA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tiziana Life Sciences ROCE % Calculation

Tiziana Life Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-18.413/( ( (11.284 - 7.348) + (11.495 - 11.209) )/ 2 )
=-18.413/( (3.936+0.286)/ 2 )
=-18.413/2.111
=-872.24 %

Tiziana Life Sciences's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-18.454/( ( (16.597 - 7.397) + (11.495 - 11.209) )/ 2 )
=-18.454/( ( 9.2 + 0.286 )/ 2 )
=-18.454/4.743
=-389.08 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -389.08% mean?
Tiziana Life Sciences (TLSA) has a ROCE % of -389.08% as of Dec. 2025.
Is Tiziana Life Sciences' ROCE % too high?
Tiziana Life Sciences' current ROCE % is -389.08%. Overall, Tiziana Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Tiziana Life Sciences' ROCE % compare to DTIL and MIST?
Tiziana Life Sciences' ROCE % of -389.08% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Tiziana Life Sciences's current ROCE % is -389.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tiziana Life Sciences stock overvalued right now?
Tiziana Life Sciences (TLSA) has a current ROCE % of -389.08%. The current ROCE % is -389.08%. Tiziana Life Sciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Tiziana Life Sciences (TLSA), the current ROCE % is -389.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tiziana Life Sciences Business Description

Other Exchanges 0RP:Germany
Address 2 Church Street, Clarendon House, Hamilton, BMU, HM 11
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
30GF Score

Get the complete analysis for TLSA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price